KBC Group NV Has $576,000 Stake in Insmed, Inc. (NASDAQ:INSM)

KBC Group NV grew its position in Insmed, Inc. (NASDAQ:INSM) by 9.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 7,551 shares of the biopharmaceutical company’s stock after buying an additional 678 shares during the period. KBC Group NV’s holdings in Insmed were worth $576,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Sowell Financial Services LLC acquired a new position in Insmed during the 1st quarter worth approximately $255,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of Insmed by 37.7% during the first quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company’s stock worth $1,521,000 after buying an additional 5,453 shares in the last quarter. M&T Bank Corp raised its stake in Insmed by 5.6% in the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 166 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 411 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in Insmed in the fourth quarter valued at about $1,864,000.

Insmed Trading Up 0.3%

Shares of NASDAQ:INSM opened at $98.50 on Friday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $106.83. The company has a market capitalization of $18.69 billion, a PE ratio of -16.55 and a beta of 0.90. The business has a 50 day moving average of $80.87 and a two-hundred day moving average of $76.42. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The business had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. During the same quarter last year, the firm earned ($1.06) earnings per share. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on INSM shares. Mizuho upped their price objective on Insmed from $96.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, June 11th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Insmed in a research report on Tuesday, June 10th. HC Wainwright increased their price target on Insmed from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, June 11th. Leerink Partners upped their price objective on Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, June 10th. Finally, Wells Fargo & Company increased their price target on Insmed from $107.00 to $119.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 11th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $106.80.

Insider Activity

In other Insmed news, CEO William Lewis sold 129,805 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the completion of the sale, the chief executive officer directly owned 233,924 shares of the company’s stock, valued at approximately $23,483,630.36. This trade represents a 35.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 57,766 shares of the firm’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $89.12, for a total value of $5,148,105.92. Following the completion of the sale, the chief financial officer directly owned 103,412 shares of the company’s stock, valued at $9,216,077.44. This represents a 35.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 488,752 shares of company stock worth $43,199,826 in the last quarter. Insiders own 3.00% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.